| Quick navigation: | Home | Site Map || References | Biography || Copyright | Other copyright | Contact us | Advert | | |
Re: [ccp4bb] Self Rotation map in R32? |
||
- Protein crystallographyMain steps:- Protein purification- Crystallisation Special:- Programs for crystallography- X-ray detectors Basic tutorials:- Chemistry- Protein - Peptide - Amino Acids Xtal community:- CCP4BB |
CCP4bb navigationCCP4bb <-- 1999 <-- November 1999 <-- 30 November 1999Subject: Re: Self Rotation map in R32? From: Charlie Bond Charles {- dot -} Bond {- at -} UWA {- dot -} EDU {- dot -} AU Date: 2009-07-21 By 'on the same scale' do you mean it is 40% of the height of the K=120 peak? Could it be a 'tail' of the kappa=120 degree peak? If you look at 95, 100, 110 etc does the peak persist and get stronger? I'm not sure how meaningful this would be, but I just had a look at the polarrfn output of a C2 dataset and I can still see 40% of the K=180 peak present at K=150. Cheers, Charlie Francis E Reyes wrote: > Ian > > Thanks for the quick reply. I enclose the missing kappa=90 slice. It is > on the same scale as the kappa=180 slice. The log doesn't report any > peaks for the kappa=90 slice (using a 10 sigma cutoff). The unit cell > parameters are 104.63 104.63 109.80, 90 90 120 and based on the contents > of my molecule, matthews_coeff is 2.34 with 64% solvent content for 4 > molecules per asu. 4-fold ncs it is then? > > Thanks > > FR > > > > On Jul 21, 2009, at 4:47 PM, Ian Tickle wrote: > >>> -----Original Message----- >>> From: owner-ccp4bb@jiscmail.ac.uk [mailto:owner-ccp4bb@jiscmail.ac.uk] >> On >>> Behalf Of Francis E Reyes >>> Sent: 21 July 2009 22:22 >>> To: ccp4bb@jiscmail.ac.uk >>> Subject: Self Rotation map in R32? >>> >>> Hi all >>> >>> I'm trying to understand why there is a peak that is perpendicular to >>> the c axis on my kappa = 180 and kappa = 90? >> >> On the kappa = 180 section they are the 3 crystallographic 2-folds perp >> to the cryst 3-fold parallel to c. >> >> On kappa = 90 a peak would be a 4-fold but since there's no obviously no >> crystallographic 4-fold in R32, that would imply 4-fold NCS, which would >> be unusual. You didn't post your kappa=90 section so we can't tell if >> it really is a significant peak. >> >>> The chapter entitled "Characterizing a Crystal From an Initial Native >>> Dataset" from Sawaya says that R32 shouldn't have a central peak in >>> kappa = 180 nor 90. >> >> Not sure what you mean by 'central peak', the peak in the middle of the >> kappa=180 section is the crystallographic 3-fold so that's unavoidable >> in R32. Again any peak on kappa=90 would depend on what kind of NCS you >> have. How many mols/a.u. do you estimate? >> >> HTH! >> >> -- Ian >> >> >> Disclaimer >> This communication is confidential and may contain privileged >> information intended solely for the named addressee(s). It may not be >> used or disclosed except for the purpose for which it has been sent. >> If you are not the intended recipient you must not review, use, >> disclose, copy, distribute or take any action in reliance upon it. If >> you have received this communication in error, please notify Astex >> Therapeutics Ltd by emailing I.Tickle@astex-therapeutics.com and >> destroy all copies of the message and any attached documents. >> Astex Therapeutics Ltd monitors, controls and protects all its >> messaging traffic in compliance with its corporate email policy. The >> Company accepts no liability or responsibility for any onward >> transmission or use of emails and attachments having left the Astex >> Therapeutics domain. Unless expressly stated, opinions in this >> message are those of the individual sender and not of Astex >> Therapeutics Ltd. The recipient should check this email and any >> attachments for the presence of computer viruses. Astex Therapeutics >> Ltd accepts no liability for damage caused by any virus transmitted by >> this email. E-mail is susceptible to data corruption, interception, >> unauthorized amendment, and tampering, Astex Therapeutics Ltd only >> send and receive e-mails on the basis that the Company is not liable >> for any such alteration or any consequences thereof. >> Astex Therapeutics Ltd., Registered in England at 436 Cambridge >> Science Park, Cambridge CB4 0QA under number 3751674 >> >> > > --------------------------------------------- > Francis Reyes M.Sc. > 215 UCB > University of Colorado at Boulder > > gpg --keyserver pgp.mit.edu --recv-keys 67BA8D5D > > 8AE2 F2F4 90F7 9640 28BC 686F 78FD 6669 67BA 8D5D > -- Charlie Bond Professorial Fellow University of Western Australia School of Biomedical, Biomolecular and Chemical Sciences M310 35 Stirling Highway Crawley WA 6009 Australia Charles.Bond@uwa.edu.au +61 8 6488 4406 CCP4bb navigationCCP4bb <-- 1999 <-- November 1999 <-- 30 November 1999 |
|
| ProteinCrystallography.org: Copyright 2006-2010 by Quid United Ltd |